ID

34480

Beschreibung

Periperal Blood Lymphocytes During Prostate RT; ODM derived from: https://clinicaltrials.gov/show/NCT01899391

Link

https://clinicaltrials.gov/show/NCT01899391

Stichworte

  1. 17.01.19 17.01.19 -
  2. 22.05.19 22.05.19 -
Rechteinhaber

see on clinicaltrials.gov

Hochgeladen am

17. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostate Cancer NCT01899391

Eligibility Prostate Cancer NCT01899391

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
intermediate-risk prostate cancer patients (t1/t2n0m0 with either gs < 7 and psa between 10-20 ng/ml or gs 7 and psa less than 20 ng/ml).
Beschreibung

ID.1

Datentyp

boolean

planned for radical rt to the prostate with imrt planning (79gy/39fractions or 60 gy/20 fractions).
Beschreibung

ID.2

Datentyp

boolean

no contraindications to diagnostic ct scanning.
Beschreibung

ID.3

Datentyp

boolean

prostate volumes will be less than 80 cc to control the planning dose volume histogram (dvh) as much as possible in terms of rectal and bladder volumes.
Beschreibung

ID.4

Datentyp

boolean

no known dna repair disorders (e.g. family history of at, brca1/2 or li fraumeni syndrome) or contraindications to radical pelvic rt.
Beschreibung

ID.5

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
inability to provide informed consent.
Beschreibung

ID.6

Datentyp

boolean

patient having contraindications to diagnostic ct scan.
Beschreibung

ID.7

Datentyp

boolean

patients who have unobtainable data regarding previous therapy and their clinical outcome.
Beschreibung

ID.8

Datentyp

boolean

patients should not have any diagnostic x-rays or cat scans 2 weeks prior to their enrollment into the study.
Beschreibung

ID.9

Datentyp

boolean

Ähnliche Modelle

Eligibility Prostate Cancer NCT01899391

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
intermediate-risk prostate cancer patients (t1/t2n0m0 with either gs < 7 and psa between 10-20 ng/ml or gs 7 and psa less than 20 ng/ml).
boolean
ID.2
Item
planned for radical rt to the prostate with imrt planning (79gy/39fractions or 60 gy/20 fractions).
boolean
ID.3
Item
no contraindications to diagnostic ct scanning.
boolean
ID.4
Item
prostate volumes will be less than 80 cc to control the planning dose volume histogram (dvh) as much as possible in terms of rectal and bladder volumes.
boolean
ID.5
Item
no known dna repair disorders (e.g. family history of at, brca1/2 or li fraumeni syndrome) or contraindications to radical pelvic rt.
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
inability to provide informed consent.
boolean
ID.7
Item
patient having contraindications to diagnostic ct scan.
boolean
ID.8
Item
patients who have unobtainable data regarding previous therapy and their clinical outcome.
boolean
ID.9
Item
patients should not have any diagnostic x-rays or cat scans 2 weeks prior to their enrollment into the study.
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video